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Abstract
Hypothesis—Many patients with lung cancers cannot receive platinum-containing regimens due 
to co-morbid medical conditions. We designed the PPB regimen of paclitaxel, pemetrexed, and 
bevacizumab to maintain or improve outcomes while averting the unique toxicities of platinum-
based chemotherapies.
Methods—We enrolled patients with untreated, advanced lung adenocarcinomas with 
measurable disease, and no contraindications for bevacizumab. Participants received paclitaxel 90 
mg/m2, pemetrexed 500 mg/m2, and bevacizumab 10 mg/kg every 14 days for six months and 
continued pemetrexed and bevacizumab every 14 days until progression or unacceptable toxicity.
Results—Forty-four patients were treated: 50% women, median age 61 years, and 89% with 
Karnofsky performance status ≥80%. We genotyped 38 patients: KRAS 16; ALK 3; BRAF V600E 
2; HER2/PIK3CA 1; EGFR exon 20 insertion 1; no driver 15. 23 patients achieved a partial 
response (52%, 95% CI 37 to 68%), including 7/16 with KRAS-mutant tumors. Overall survival at 
two years was 43% with a median of 17 months (95% CI, 10 to 29). Grade 3/4 treatment-related 
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toxicities included elevated ALT (16%); fatigue (16%); leukopenia (9%); anemia (7%); elevated 
AST (7%); edema (5%) and pleural effusions (5%). Two patients died of respiratory failure 
without disease progression.
Conclusions—The PPB regimen of paclitaxel, pemetrexed, and bevacizumab produced a high 
response rate in patients with lung adenocarcinomas, regardless of mutational status. Survival and 
toxicities were comparable to phase II reports testing platinum-containing doublets with 
bevacizumab. These results justify use of the PPB regimen in fit patients where 3 drug regimens 
including bevacizumab are appropriate.
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Introduction
Cisplatin- or carboplatin-containing doublets with or without bevacizumab are standard 
initial treatments for patients with advanced lung adenocarcinomas.1 However, many 
patients with lung cancers cannot receive cisplatin or carboplatin because of baseline 
neuropathy, hearing loss, renal insufficiency, heart failure, or other comorbid medical 
conditions. Since the majority of patients diagnosed with lung cancers are over age 70,2 
these toxicities are more likely and more severe.3 The addition of bevacizumab to a 
platinum-containing doublet improves response, progression-free survival and overall 
survival.4, 5
Pemetrexed improves survival in patients with adenocarcinomas when administered both 
initially with cisplatin 6 and as maintenance.7 As the agent is well tolerated, with 
predominant side effects being myelosuppression and fatigue, combination therapy and 
prolonged administration are possible.6-8 Bevacizumab has been widely used with 
pemetrexed, studied in combination with carboplatin or cisplatin as initial therapy that is 
then continued until progression.9-12 Progression-free survival significantly improved for 
patients receiving pemetrexed/carboplatin/bevacizumab followed by pemetrexed/
bevacizumab compared to paclitaxel/carboplatin/bevacizumab followed by bevacizumab 
alone.11 A second trial which randomized patients to either pemetrexed/bevacizumab or 
bevacizumab alone after induction with pemetrexed/cisplatin/bevacizumab, also 
demonstrated a significant improvement in progression-free survival in patients continuing 
both agents after cisplatin therapy was completed.9, 10
Numerous studies have tested regimens without cisplatin or carboplatin, utilizing 
combinations of gemcitabine, paclitaxel, docetaxel, and vinorelbine.13-19 In one phase I/II 
trial evaluating the two-drug combination of pemetrexed with paclitaxel, the response rate 
was 40%, with 1 year survival of 65%, and a grade 3/4 neutropenia rate of 17%.20 A meta-
analysis comparing non-platinum to platinum-containing doublets 21 found no difference in 
overall survival and response between the two types of regimens.
To develop a non-platinum-containing regimen using two active agents plus bevacizumab, 
we conducted this trial of PPB, the combination of paclitaxel, pemetrexed, and bevacizumab. 
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The regimen was designed empirically to substitute pemetrexed for carboplatin in the 
carboplatin-paclitaxel-bevacizumab regimen in worldwide use. Pemetrexed is highly active 
in lung adenocarcinomas and has bested gemcitabine when each was combined with 
cisplatin in a head-to-head comparison in persons with lung adenocarcinomas. Previous 
trials have shown that pemetrexed can be combined with either paclitaxel or bevacizumab. 
This regimen was designed for use in “fit” patients who are candidates to receive a 
chemotherapy doublet and bevacizumab. Appropriate patients must have a performance 
status of 70% or greater, normal kidney, liver and bone marrow function, and no 
contraindications specific to the drugs that are part of the PPB regimen (allergy, hemoptysis, 
squamous cell histology, recent stroke or heart attack, or peripheral neuropathy greater than 
1+).
Materials and Methods
This single arm, open label, single-institution phase II study was reviewed and approved by 
the Institutional Review Board. All patients provided written informed consent.
Eligibility
All patients had pathologically confirmed lung adenocarcinomas with stage IV disease at 
diagnosis or metastatic recurrence after definitive local therapy. Inclusion also required 
Karnofsky Performance Status of ≥70%, and measurable disease per Response Evaluation 
Criteria in Solid Tumors (RECIST 1.0).22 Patients had leukocytes >4000/mm3; platelets 
>160,000/mm3; bilirubin <1.2 mg/dL; creatinine clearance ≥40mL/min; alanine 
aminotransferase and/or aspartate aminotransferase ≤37Units/L (or if one elevated, ≤2.5 
times the upper limit of normal); and systolic blood pressure ≤ 150mmHg. Prior neoadjuvant 
or adjuvant chemotherapy was permitted if it did not contain paclitaxel, pemetrexed or 
bevacizumab and at least 6 months had elapsed from the date of last administration.
Patients were excluded if they had received systemic therapy for advanced lung cancers or 
radiation therapy to greater than 25% of the bone marrow within 30 days of starting 
treatment. Additional exclusion criteria included squamous cell carcinomas, small cell 
carcinomas, hemoptysis; symptomatic brain metastases with evidence of hemorrhage; 
history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess; and 
myocardial infarction or stroke within 6 months.
Treatment
Patients were initially treated with paclitaxel 90 mg/m2 over 60 minutes on days 1, 8, and 15 
in addition to pemetrexed 500 mg/m2 over 10 minutes, and bevacizumab 10 mg/kg over 20 
minutes every 14 days. Seven of the first 11 patient who received paclitaxel on days 1, 8, and 
15 of each cycle developed AST and ALT elevations. The protocol was amended and the day 
8 visits and paclitaxel dose were omitted for all subsequent patients. The trial was amended 
again to permit patients with dose-limiting paclitaxel-related side effects to continue on 
study without paclitaxel or paclitaxel could be replaced by albumin-bound paclitaxel if a 
hypersensitivity reaction to paclitaxel occurred. Each cycle consisted of 28 days, and was 
repeated up to six times. Subsequently, pemetrexed and bevacizumab were administered 
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every 14 days until progression or unacceptable toxicity. The planned dose intensity for the 
recommended PPB regimen was 250 mg/m2 per week for pemetrexed, 5 mg/kg per week for 
bevacizumab, and 45 mg/m2 per week for paclitaxel (60 mg/m2 per week if albumin-bound 
paclitaxel is used).
Dosing of paclitaxel and pemetrexed was delayed at the start of a cycle for neutrophil count 
<3,000/μl and/or platelets <100,000/μl and, within a cycle for neutrophil count < 1.0 × 109 
cells/L and/or platelets < 75 × 109 cells/L. With the development of grade ≥ 1 to grade ≤ 3 
AST and ALT or grade ≥2 pneumonitis/pulmonary infiltrates, paclitaxel was held. 
Pemetrexed was held if creatinine clearance ≤ 40mL/minute or for grade ≥ 2 mucositis or 
diarrhea. Upon resuming paclitaxel or pemetrexed, two dose reductions were permitted for 
paclitaxel (75mg/m2 and 60mg/m2) and pemetrexed could be reduced to 375 mg/m2.
Study Evaluations
Patients were assessed on days 1 and 15 of each 28-day cycle with a history, physical 
examination, toxicity assessment, complete blood count, and comprehensive metabolic 
panel. Patients were asked to electronically self-report 13 toxicity- and disease-related 
symptoms using a Symptom Tracking and Reporting (STAR) system, a validated patient 
version of the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) version 3.0.23-26 The symptoms/toxicities collected via the STAR platform 
included: fatigue, alopecia, epiphora, epistaxis, hoarseness, nausea, mucositis/stomatitis, 
cough, dyspnea, pain, sensory peripheral neuropathy, anorexia, Karnofsky Performance 
Status, and myalgias. During the visits, STAR data were provided to clinicians, who then 
had the option to either accept or modify the grade of these symptoms and toxicities based 
on their own assessments. The final CTCAE grade and attribution were assigned by the 
clinician.23
Tumor assessments at baseline included a computed tomography (CT) of the chest, abdomen 
and pelvis, as well as other relevant sites of disease, and a contrast-enhanced MRI or CT of 
the brain. Follow-up scans to assess response were obtained after cycles 1, 2, 4 and 6, then 
every three months. Responses were determined using RECIST 1.0.22 All imaging studies 
were reviewed by a reference radiologist (MSG).
Statistical Analysis
The primary endpoint was overall response rate (complete response (CR) plus partial 
response (PR)). Secondary endpoints included progression-free and overall survival and 
assessment of side-effects. A Simon two-stage design was used to determine the sample size. 
The null and desired response rates were chosen to be 15% and 35%, respectively. If at least 
3 responses were noted among the 19 patients in stage 1, enrollment would be extended to 
44. At the end of the trial, if 11 or more of 44 total patients were found to have a complete or 
partial response, the regimen would be considered effective. This design had a 90% power to 
detect the difference at a 5% type I error rate. Overall response rates, along with exact two-
sided 95% confidence intervals (CI) were calculated. Progression-free and overall survivals 
were estimated from the date of first treatment using the Kaplan-Meier method.
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Additional Objectives
We also assessed the feasibility of obtaining response and side-effect data from this trial in 
real-time by: a) collecting patient reported outcomes (toxicities and disease-related 
symptoms) using wireless touch screen laptop computers in the outpatient facilities via the 
MSK STAR system, with storage of this information in the MSK institutional database (by 
EMB, MS, MS, LJR), b) using an automated response assessment algorithm to determine 
uni dimensional (RECIST 1.0) measurements of indicator lesions. Measurements were 
determined and response data were automatically downloaded into the MSK institutional 
database (by LHS and MSG), and c) collecting clinician-generated data using a web-based 
portal, StudyTracker, that automatically downloaded information into the MSK institutional 
data base (by AL). Each of these objectives was achieved in the context of this trial and 
reported.23, 27-29
Results
Patients
We enrolled 44 patients between January 2009 and September 2011. Baseline characteristics 
are listed in Table 1. The majority of the patients were former smokers.
Drug Delivery
The median number of drug doses and range for each of the agents in the regimen are as 
follows: pemetrexed 10 doses (range 1 to 36), paclitaxel 6 doses (range 1 to 15) and 
bevacizumab 11 doses (range 1 to 83). The delivered dose intensity was 220 mg/m2/wk for 
pemetrexed, 29 mg/m2/wk for paclitaxel, and 4.3 mg/kg per week for bevacizumab. Four 
patients were treated with albumin-bound paclitaxel after experiencing a hypersensitivity 
reaction with paclitaxel. They received 1, 2, 5, and 33 doses of albumin-bound paclitaxel 
without further hypersensitivity symptoms. Fifty percent of the patients (N = 22) completed 
six cycles of therapy with paclitaxel, pemetrexed, and bevacizumab (median number of 
cycles in overall cohort, 6; range 1 to 6). Only 2 patients who completed 6 cycles of initial 
therapy did not continue with maintenance, both due to progression of disease. Twenty 
patients overall (45%) received at least one dose of pemetrexed and bevacizumab (median 
number of cycles, 5; range 1-36) after the induction phase (see Figure 1).
Response and Survival
The overall response rate (complete and partial) was 52% (23/44; 95% CI 37 to 68%) 
(Figure 2). Four additional patients had unconfirmed partial responses. The objective 
response rate in KRAS-mutant lung cancers, the largest molecularly defined subgroup, was 
44% (7/16; 95% CI 23% to 67%). Response could not be determined in 2 patients who did 
not have follow-up imaging studies, but were included in the denominator for response rate. 
The median progression free and overall survivals for the entire cohort (n=44) were 8 
months (95% CI 5 to 11) and 17 months (95% CI 10 to 29), respectively (Figure 3). The 
overall survival rates were 64% at 1 year, 43% at 2 years, and 25% at 3 years.
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Effect of PPB on Symptoms of Lung Cancers Assessed by STAR
Baseline and on-study grading of symptoms of lung cancers are presented in Table 2. The 
majority of patients with baseline fatigue, pain, dyspnea, cough, and anorexia experienced 
an improvement of at least 1 CTCAE grade while receiving PPB.
Treatment-Related Toxicities
Table 3 summarizes treatment-related toxicities. Paclitaxel was stopped in 7 patients (16%) 
due to hypersensitivity reactions occurring despite standard premedication. We continued the 
three drug regimen in 4 of these patients by replacing paclitaxel with albumin bound 
paclitaxel (120 mg/m2 given over 2 hours without premedication) every 14 days with 
pemetrexed and bevacizumab30, 31 with no further hypersensitivity symptoms. Grade 3 
elevations of ALT occurred in 16% and AST in 7%. There were no grade 4 elevations. 
Although anemia and leukopenia commonly occurred, only one patient developed febrile 
neutropenia. Grade 3 lower extremity edema and pleural effusions occurred in 2 patients. 
One patient developed edema, a pleural effusion and an asymptomatic pericardial effusion, 
which required drainage. Possible bevacizumab-related side effects included one grade 2 
osteonecrosis of the jaw, one grade 2 ischemic event resulting in a partial palsy of cranial 
nerve IV, one grade 3 wound healing event, and one grade 3 small bowel perforation. One 
patient developed grade 3 pneumonitis and recovered following treatment with 
corticosteroids. Two patients (5%) died of respiratory failure without evidence of disease 
progression. Both individuals presented with dyspnea and bilateral infiltrates and died 
despite treatment with corticosteroids, antibiotics, and mechanical ventilation.
Molecular Characteristics
Tumor samples for molecular testing were available from 38 patients (86%). (Table 1) We 
genotyped 38 patients: KRAS 16; ALK 3; BRAF V600E 2; HER2/PIK3CA 1; EGFR exon 
20 insertion 1; no driver 15. We documented a partial response in 9 of the 15 individuals 
with tumors with no oncogenic driver identified. We confirmed partial responses in all 3 
patients with ALK-positive lung cancers, the 2 with BRAF-driven tumors and the one 
individual with an EGFR exon 20 insertion. Following study-treatment discontinuation, 2 of 
the 3 patients whose tumors harbored ALK-rearrangements were treated with crizotinib and 
both patients with BRAF V600E-mutant adenocarcinomas received vemurafenib.
Additional Therapies
Overall, 84% of patients (N = 32) received subsequent therapy, with a median of two (range, 
1 to 4) additional regimens.
Discussion
This phase II study explored PPB, a non-platinum containing regimen of paclitaxel and 
pemetrexed with bevacizumab in patients with advanced lung cancers. We found a 52% 
overall response rate, which met the primary end point of this study and exceeded the 35% 
response rate we hypothesized. Responses to this regimen were seen across adenocarcinoma 
genotypes, including tumors with no oncogenic drivers identified and those with KRAS 
mutations. For patients with EGFR- and ALK-positive lung cancers, we recommend that 
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matched targeted therapies be given before PPB. The huge experience favoring targeted 
therapies over cisplatin or carboplatin containing chemotherapies in patients with EGFR and 
ALK-positive lung cancers applies to PPB as well. Toxicities were comparable to the phase 
II experiences with platinum-containing doublets with bevacizumab. 12, 32, 33
Our study differed from the previous evaluations of non-platinum doublet regimens with 
third generation chemotherapy agents13-19, 21 as it included bevacizumab, and allowed for 
pemetrexed and bevacizumab to continue until progression (maintenance therapy), which 
has become a standard of care in patients with response to initial therapy.1 The design and 
outcomes of this trial were similar to the 50 patient phase II study of pemetrexed and 
carboplatin with bevacizumab followed by maintenance pemetrexed and bevacizumab, 
reported by Patel.12 The overall response rate was 55% and median progression free and 
overall survivals were 8 and 14 months respectively.12 Three patients died on that study, one 
without disease progression. In a 34 patient phase II trial of paclitaxel, carboplatin, and 
bevacizumab (15 mg/m2) without maintenance, the overall response rate was 32% and 
median time to progression and overall survival were 7 and 18 months respectively.32 Four 
patients died on this study, all without disease progression. In a recent 67 patient phase II 
trial of paclitaxel, carboplatin, and bevacizumab with maintenance, the overall response rate 
was 63% and median progression free and overall survivals were 7 and 16 months 
respectively. 33 One patient died on study without disease progression. Keeping in mind the 
limitations of cross trial analyses, the response rates, survival, and number of on study 
deaths without disease progression seen in our phase II study are comparable to the phase II 
results with platinum-containing regimens reported by Patel, Johnson, and Besse.12, 32, 33
Fifty percent of patients completed the planned six cycles of pemetrexed, paclitaxel, and 
bevacizumab and, at progression, 84% of patients went on to receive additional 
chemotherapeutic agents. There were few grade 3/4 hematologic toxicities and only 1 
episode of febrile neutropenia. Paclitaxel was stopped in 7 patients due to hypersensitivity 
reactions occurring despite standard premedication. We continued the three drug regimen in 
four by replacing paclitaxel with albumin bound paclitaxel (120 mg/m2 given over 2 hours) 
every 14 days with the pemetrexed and bevacizumab30, 31 with no further hypersensitivity 
symptoms. Based on our experience, we would substitute albumin-bound paclitaxel for 
paclitaxel in this regimen if albumin-bound paclitaxel is available. Initially, we noted 
elevations of AST and ALT with a day 8 dose of paclitaxel. After enrolling 11 patients, we 
amended the protocol to eliminate the day 8 paclitaxel dose. After this modification, patients 
were then able to receive the expected doses of paclitaxel given every 2 weeks with the other 
agents. Other studies evaluating frequent administrations of paclitaxel have not reported high 
rates of AST and ALT abnormalities.34, 35 This was also not noted in a prior trial of the 
combination of paclitaxel and pemetrexed.20 Bevacizumab is not known to cause or 
accentuate AST and ALT abnormalities alone or in combination.
Grade 3 edema and pleural effusions occurred in 5% of patients, a finding which had not 
been reported in other trials evaluating the combination of pemetrexed and bevacizumab or 
pemetrexed alone.8, 9, 12, 36, 37 One patient also developed a pericardial effusion, attributed 
to pemetrexed. All the effusions occurring without progression at other disease sites were 
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transudates containing no malignant cells. These events have been described. The 
mechanism is not known.38, 39
Pulmonary toxicity has been described in patients receiving paclitaxel, pemetrexed, and the 
combination.40-44 While hypersensitivity has been implicated in paclitaxel-induced lung 
toxicity40, 43 no mechanism has been proposed for pemetrexed. Diffuse alveolar damage was 
detected in one report.44 Patients on this or any regimen with pemetrexed and paclitaxel 
should be monitored for clinical and radiographic signs of pulmonary toxicity and 
corticosteroids should be started promptly whenever treatment-related pulmonary toxicity is 
a consideration.
The high rate of response seen with the PPB regimen, that increases the dose intensity of 
pemetrexed and requires visits every two weeks instead of every three, comes at the expense 
of increased cost. Physicians and patients in each case together need to decide whether the 
potential benefits in response and symptom improvement with PPB are sufficient to offset 
the additional financial and time expenditures associated with this regimen. Cost also varies 
with each country and health care system, necessitating decision making on a case-by-case 
basis.
PPB, a three drug combination of pemetrexed, paclitaxel, and bevacizumab produced a 52% 
overall response rate and a one year survival of 64% as an initial therapy in patients with 
lung adenocarcinomas. This non-platinum-containing chemotherapy regimen including 
bevacizumab met the study specified definition of effectiveness and improved symptoms of 
lung cancers. Toxicities were comparable to phase II experiences with platinum doublet 
regimens plus bevacizumab. This regimen is worthy of further evaluation and use in patients 
fit to receive three drug regimens including bevacizumab.
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Figure 1. Paclitaxel and pemetrexed with bevacizumab (PPB) CONSORT diagram
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Figure 2. Best change from baseline in measurable lesion size for 42 patients with evaluable 
indicator lesions: Waterfall Plot
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Figure 3. Overall progression-free and overall survival from the date of start of paclitaxel, 
pemetrexed, and bevacizumab (PPB) treatment (n=44)
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Table 1
Patients
Enrolled 44
Women/Men 22/22
Median Age (Range) 61 (31 – 77)
Karnofsky Performance Status
 ≥90% 19 (43%)
 80% 20 (46%)
 70% 5 (11%)
Cigarette Smoking History
 Never 7 (16%)
 Former 30 (68%)
 Current 7 (16%)
 Median Pack-Years Smoked (Range) 38 (10 – 120)
Brain Metastases
 No 32 (73%)
 Yes 12 (27%)
  Treated 11 (92%)
  Untreated 1 (8%)
Oncogenic Drivers Identified
 KRAS‡ 16 (36%)
 ALK 3 (7%)
 BRAF V600E 2 (5%)
 EGFR exon 20 Insertion 1 (2%)
 HER2/PIK3CA 1 (2%)
 None 15 (34%)
 Not Tested 6 (14%)
‡KRAS mutations: G12V (N = 3), G12C (N = 7), G12A (N = 2), G12D (N = 3), G13D (N =1)
J Thorac Oncol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Pietanza et al. Page 17
Table 2
Patient reported symptoms of lung cancers collected using the Symptom Tracking and 
Reporting (STAR) System26-30; baseline CTCAE grades and improvement while on 
treatment with paclitaxel and pemetrexed with bevacizumab (PPB) by at least one grade 
in patients with baseline symptoms
Symptoms Of Lung 
Cancers
Baseline Grades of Patient Reported Symptoms (%) Percent of Patients with Baseline Symptoms with 
Improvement of at Least One Grade While on 
StudyGrade 0 Grade 1 Grade ≥2
Fatigue 34 50 16 50%
Pain 36 46 18 82%
Dyspnea 48 36 16 77%
Cough 64 23 13 100%
Anorexia 66 25 9 86%
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